Advertisement

Topics

70% Dextrose Injection, USPPharmacy Bulk PackageNot for Direct InfusionVIAFLEX Plastic ContainerA Parenteral Nutrient | DEXTROSE [Baxter Healthcare Corporation] | BioPortfolio

12:30 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Dextrose Injections, USP are sterile, nonpyrogenic hypertonic solutions for fluid replenishment and caloric supply in Pharmacy Bulk Package. A Pharmacy Bulk Package is a container of sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous infusion. They contain no antimicrobial agents. Composition, osmolarity, pH, and caloric content are shown below.

The VIAFLEX plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period. The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly.

Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as tissue culture toxicity studies.

Table 1
Composition Osmolarity Caloric Content How Supplied
Dextrose Hydrous, USP (g/L) (mOsmol/L) (calc.) pH (kcal/L) Size, code, NDC
2000 mL unit
70% Dextrose Injection, USP 700 3530 4.0 (3.2 to 6.5) 2390 2B0296 NDC 0338-0719-06

Dextrose Injection, USP have value as a source of water and calories. They are capable of inducing diuresis depending on the clinical condition of the patient.

Dextrose Injection, USP are indicated as a caloric component in a parenteral nutrition regimen. They are used with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: (1) the alimentary tract cannot or should not be used, (2) gastrointestinal absorption of protein is impaired, or (3) metabolic requirements for protein are substantially increased, as with extensive burns.

The infusion of hypertonic dextrose injections is contraindicated in patients having intracranial or intraspinal hemorrhage, in patients who are severely dehydrated, in patients who are anuric, and in patients in hepatic coma.

Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.

These injections are for compounding only, not for direct infusion.

Dilute before use to a concentration which will, when administered with an amino acid (nitrogen) source, result in an appropriate calorie to gram of nitrogen ratio and which has an osmolarity consistent with the route of administration.

Unless appropriately diluted, the infusion of hypertonic dextrose injection into a peripheral vein may result in vein irritation, vein damage, and thrombosis. Strongly hypertonic nutrient solutions should only be administered through an indwelling intravenous catheter with the tip located in a large central vein such as the superior vena cava.

In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible intracerebral hemorrhage.

WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

Administration by central venous catheter should be used only by those familiar with this technique and its complications.

Monitor changes in fluid balance, electrolyte concentration, and acid base balance during prolonged parenteral therapy or whenever the conditions of the patient warrants such evaluation.

Administration of hypertonic dextrose and amino acid solutions via central venous catheter may be associated with complications which can be prevented or minimized by careful attention to all aspects of the procedure. This includes attention to solution preparation, administration and patient monitoring.

It is essential that a carefully prepared protocol, based upon current medical practice, be followed, preferably by an experienced medical team.

The package insert of the protein (nitrogen) source should be consulted for dosage and all precautionary information.

Monitor changes in fluid balance, electrolyte concentration, and acid base balance during prolonged parenteral therapy or whenever the conditions of the patient warrants such evaluation.

Care should be taken to avoid circulatory overload, particularly in patients with cardiac insufficiency.

Caution must be exercised in the administration of these injections to patients receiving corticosteroids or corticotropin.

These injections should be used with caution in patients with overt or subclinical diabetes mellitus.

Drug product contains no more than 25 mcg/L of aluminum.

There are no adequate and well controlled studies with Dextrose Injections, USP in pregnant women and animal reproduction studies have not been conducted with this drug. Therefore, it is not known whether Dextrose Injections, USP can cause fetal harm when administered to a pregnant woman. Dextrose Injections, USP should be given during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Intrapartum maternal intravenous infusion of glucose-containing solutions may produce maternal hyperglycemia with subsequent fetal hyperglycemia and fetal metabolic acidosis. Fetal hyperglycemia can result in increased fetal insulin levels which may result in neonatal hypoglycemia following delivery. Consider the potential risks and benefits for each specific patient before administering Dextrose Injections, USP.

It is not known whether this drug is present in human milk. Because many drugs are present in human milk, caution should be exercised when 70% Dextrose Injection, USP is administered to a nursing woman.

The use of Dextrose in pediatric patients is based on clinical practice (see DOSAGE AND ADMINISTRATION). Because of their hypertonicity, 70% Dextrose Injections must be diluted prior to administration.

Newborns – especially those born premature and with low birth weight - are at increased risk of developing hypo- or hyperglycemia and therefore need close monitoring during treatment with intravenous glucose solutions to ensure adequate glycemic control in order to avoid potential long term adverse effects. Hypoglycemia in the newborn can cause prolonged seizures, coma and brain damage. Hyperglycemia has been associated with intraventricular hemorrhage, late onset bacterial and fungal infection, retinopathy of prematurity, necrotizing enterocolitis, bronchopulmonary dysplasia, prolonged length of hospital stay, and death.

Too rapid infusion of a hypertonic dextrose solution may result in diuresis, hyperglycemia, glycosuria, and hyperosmolar coma. Continual clinical monitoring of the patient is necessary in order to identify and initiate measures for these clinical conditions.

Hypersensitivity reactions, including anaphylaxis and chills.

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

If an adverse reaction does occur discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.

Following suitable admixture of prescribed drugs, the dosage is usually dependent upon age, weight and clinical condition of the patient as well as laboratory determinations. See directions accompanying drugs.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Do not administer unless solution is clear and seal is intact.

Use of a final filter is recommended during administration of all parenteral solutions where possible.

The dosage selection and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/ hypoglycemia. Frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants. The infusion rate and volume depends on the age, weight, clinical and metabolic conditions of the patient, concomitant therapy and should be determined by the consulting physician experienced in pediatric intravenous fluid therapy.

70% Dextrose Injection, USP in the Pharmacy Bulk Package is intended for use in the preparation of sterile, intravenous admixtures. Additives may be incompatible with the fluid withdrawn from this container. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. When compounding admixtures, use aseptic technique. Mix thoroughly. Do not store any unused portion of the 70% Dextrose Injection, USP.

Tear overpouch at slit and remove solution container. Visually inspect the container. If the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired.

For compounding only, not for direct infusion.

See Table 1.

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended the product be stored at room temperature (25°C/77°F).

Baxter Healthcare Corporation Deerfield, IL 60015 USA

Printed in USA

Distributed in Canada by Baxter Corporation Mississauga, ON L5N 0C2

Baxter, PL 146, and Viaflex are trademarks of Baxter International Inc.

07-19-69-266 Revised December 2014

Container Label

LOT EXP

2B0296 NDC 0338-0719-06

2000 mL DIN 02014874

DEXTROSE Injection USP

70%

Pharmacy Bulk Package Not For Direct Infusion Must Be Diluted

Rx Only

EACH 100 mL CONTAINS 70 g DEXTROSE HYDROUS USP IN WATER FOR INJECTION USP

pH 4.0 (3.2 to 6.5) SPECIFIC GRAVITY 1.24 (CALC)

HYPERTONIC OSMOLARITY 3530 mOsmol/L (CALC)

STERILE NONPYROGENIC

CONTAINS NO MORE THAN 25 µg/L OF ALUMINUM

COLOR VARIATION FROM LIGHT YELLOW TO AMBER IS NORMALAND DOES NOT ALTER EFFICACY

DOSAGE AND ADMINISTRATION SEE PACKAGE INSERT

CAUTION DO NOT USE UNLESS SOLUTION IS CLEAR CLOSUREIS INTACT AND CONTAINER IS UNDAMAGED

CHECK FOR MINUTE LEAKS BY SQUEEZING FIRMLYIF LEAKS ARE FOUND DISCARD AS STERILITY MAY BE IMPAIRED

AFFIX ACCOMPANYING LABEL FOR DATE AND TIME OF ENTRY

WITHIN 4 HOURS AFTER INITIAL ENTRY DISCARD CONTAINER AND UNUSED CONTENTS

STORE UNIT IN MOISTURE BARRIER OVERWRAP AT ROOM TEMPERATURE (25°C/77°F) UNTIL READY TO USE AVOID EXCESSIVE HEAT PROTECT FROM FREEZING

VIAFLEX CONTAINER

PL 146 PLASTIC

Baxter Logo

BAXTER HEALTHCARE CORPORATION DEERFIELD IL 60015 USA

DISTRIBUTED IN CANADA BY BAXTER CORPORATION Mississauga, ON L5N 0C2

MADE IN USA

BAXTER PL 146 AND VIAFLEX ARE TRADEMARKS OF BAXTER INTERNATIONAL INC

70%

Carton Label

2B0296H

6 - 2000ML VIAFLEX CONTAINER

70% DEXTROSE INJECTION, USP(70% DEXTROSE IN WATER)

PROTECT FROM FREEZING

EXPXXXXX

SECONDARY BAR CODE(17) YYMM00 (10) XXXXX

LOTXXXXX

PRIMARY BAR CODE(01) 50303380719063

Manufacturer

Baxter Healthcare Corporation

Active Ingredients

Source

Drugs and Medications [241 Associated Drugs and Medications listed on BioPortfolio]

Haemonetics anticoagulant citrate dextrose solution [haemonetics corporation]

Haemonetics Anticoagulant Citrate Dextrose Solution

Diltiazem hcl [cantrell drug company]

Diltiazem HCl 250 mg in 5% Dextrose 300 mL Bag

Dextrose [baxter healthcare corporation]

5% Dextrose Injection, USP

Morphine sulfate [cantrell drug company]

Morphine Sulfate 1 mg/mL in 5% Dextrose 100 mL Bag

Amiodarone hcl [cantrell drug company]

Amiodarone HCl 900 mg Added to 5% Dextrose 500 mL Bag

Clinical Trials [114 Associated Clinical Trials listed on BioPortfolio]

40% Orally Administered Dextrose Gel is More Effective Than 25% Dextrose

The aim of this study was to evaluate the safe of 40% Dextrose oral administration on blood glucose concentration and to reducing of pain before painful procedures on healthy term neonate ...

Changes in Cytokine Levels After Dextrose Injection in Stage IV Knee Osteoarthritis

Twenty participants with severe arthritis will be enrolled. For the first week participants will either be injected with dextrose or just have fluid withdrawn for testing. The remaining pa...

Ulnar Wrist Pain Treatment With Dextrose Prolotherapy

Participants with wrist pain on the little finger side of the wrist will received either usual care, consisting of ultrasound, specialized massage and stabilization exercises therapy for 6...

Delto-Tricipital Compression Syndrome: Treated With Injection of Dextrose

The posterior antebrachial cutaneous nerve (PACN) can be compressed between the deltoid and triceps, with resultant pain and dysfunction. The active treatment for this study will be injec...

Effects of Hypertonic Dextrose Water Injection for Supraspinatus Tendinosis Patients

Using hypertonic dextrose water for chronic supraspinatus tendonitis and using ultrasound as assessment tool to evaluate the effect of intervention.

PubMed Articles [38 Associated PubMed Articles listed on BioPortfolio]

Comparison of imaged capillary isoelectric focusing and cation exchange chromatography for monitoring dextrose-mediated glycation of monoclonal antibodies in infusion solutions.

Intravenous (IV) infusion of therapeutic proteins typically involves dilution of the formulated product into infusion media such as normal saline or dextrose, 5% m/v in water. We report results from a...

Effects of hypertonic dextrose and paraffin solution as non-antibiotic treatments of clinical endometritis on reproductive performance of high producing dairy cows.

The objective of this study is to compare the reproductive performance of cows affected by clinical endometritis (CE) following treatment with an intrauterine infusion of 50% dextrose solutions (DEX) ...

Hypertonic milk replacers increase gastrointestinal permeability in healthy dairy calves.

Hypertonic milk replacers are commonly used in animal production systems and their effect on the gastrointestinal system of young animals is insufficiently studied. Total lactose inclusion or its part...

Embolization of a Complex Facial Arteriovenous Malformation, Balloon-Assisted Flow Arrest, and Controlled n-BCA Injection with Dextrose Push Technique: 2-Dimensional Operative Video.

N-butyl cyanoacrylate glue (n-BCA, Cerenovus, Irvine, California) is commonly used to treat arteriovenous malformation (AVM). Even though Onyx (ethylene vinyl alcohol, Medtronic, Dublin, Ireland) pres...

Stability of mycophenolate mofetil in polypropylene 5% dextrose infusion bags and chemical compatibility associated with the use of the EQUASHIELD® closed-system transfer device.

Stability studies are necessary in healthcare settings as they facilitate fast, cost-effective and efficient work related to batch manufacturing and availability of supplies. We studied the stability ...

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Food
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record